Format

Send to

Choose Destination
Clin Immunol. 2015 Nov;161(1):23-30. doi: 10.1016/j.clim.2015.04.021. Epub 2015 May 13.

Proteomics and autoimmune kidney disease.

Author information

1
Nephrology Division, The Ohio State University Wexner Medical Center, Columbus, OH, United States. Electronic address: Rovin.1@osu.edu.
2
Nephrology Division, The University of Louisville School of Medicine, Robley Rex VA Medical Center, Louisville, KY, United States.

Abstract

Proteomics has long been considered an ideal platform, and urine an ideal source for biomarker discovery in human autoimmune kidney diseases. A number of studies have examined the urine proteome to identify biomarkers of disease activity, kidney pathology, and response to therapy. Increasingly, proteomic studies of kidney disease have expanded to include blood, circulating cells and kidney tissue. Recently the clinical potential of renal proteomics has been realized through a handful of investigations whose results appear to be applicable to patient care. In this review, approaches to the proteomic evaluation of autoimmune kidney diseases will be considered in the context of developing clinically useful disease biomarkers.

KEYWORDS:

Proteomics

PMID:
25979820
PMCID:
PMC4628556
DOI:
10.1016/j.clim.2015.04.021
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center